The DOI matches its Crossref record.
Abstract 5789: Discovery of a selective molecular glue degrader of CCNE1 for the treatment of CCNE1-amplified solid tumors and CDK4/6i-resistant HR+/HER2- breast cancers
Abstract
Cyclin E1 (CCNE1) is a central regulator of the G1 to S-phase transition of the cell cycle and a key dependency in multiple solid tumor types, including ovarian and endometrial cancers, and promotes resistance to CDK4/6 inhibitors in HR+/HER2- breast cancer. CCNE1 lacks a druggable pocket or enzymatic activity, which has precluded attempts to develop drugs that inhibit its function. Efforts to inhibit CCNE1 activity indirectly with CDK2 kinase inhibitors have been hindered by poor selectivity and dose-limiting toxicities that prevent full pathway suppression. Here we report the discovery of a molecular glue degrader (MGD) that co-opts the CRL4CRBN E3 ubiquitin ligase to eliminate the CCNE1 protein. Single-particle cryo-electron microscopy identifies a novel non-G-loop degron on CCNE1 that drives direct recognition of CCNE1 by the MGD:CRBN:DDB1 complex without preventing CDK2 binding to CCNE1. In cell lines analyzed, MGD treatment triggers rapid, CRBN-dependent depletion of CCNE1 with complete selectivity over the rest of the proteome. MGD-induced CCNE1 degradation exerts potent and selective anti-proliferative effects, with over 500-fold greater potency in CCNE1 amplified lines compared to non-amplified lines, a substantial improvement relative to CDK2 inhibitors (∼15-fold potency window). In HR+/HER2- breast cancer cell lines with evolved resistance to the combination of a CDK4/6 inhibitor and fulvestrant, co-treatment with the MGD restores sensitivity. Oral administration of the MGD drives robust CCNE1 reduction and antitumor activity in a CCNE1-amplified xenograft model. These data suggest that directly and selectively degrading CCNE1 could provide an effective targeted therapy for CCNE1-amplified solid tumors and overcome resistance to CDK4/6 inhibitors in HR+/HER2- breast cancer. Citation Format: Benjamin M. Vincent, David Marcoux, Claudia Caligioni, Aaron G. Bart, Matt L. Harlow, Rosaline Y. Hsu, Prashant Singh, Rachel Badger, Andrew J. Ingersoll, Thomas B. Jordan, Hari B. Kamadurai, Christine Zarate, Nico R. Cantone, Aravind Prasad Medikonda, Artyom A. Alekseyenko, Duncan E. Nunes, Taras Dauzhenka, Anushka Bhagwat, David Y. Rhee, Patrick R. Arsenault, Andrew R. Conery, Alex Constan, Louis Plamondon, Tim J. Wigle, Daniel S. La, Kathleen I. Seyb, Patrick Trojer, Vito J. Palombella, . Discovery of a selective molecular glue degrader of CCNE1 for the treatment of CCNE1-amplified solid tumors and CDK4/6i-resistant HR+/HER2- breast cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5789.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent public disclosures by biotech companies have reported additional non G-loop targets, including CCNE1 (50), ARNT (51), CDK2 (52), ALK (53)”
From Degron-independent recruitment of KAT2A expands the target space of CRBN molecular glues (2026) · cites this paper as [50]
Citations
Cites
Still being checked.
Cited by
Degron-independent recruitment of KAT2A expands the target space of CRBN molecular glues
Ojeda, S., Wang, M., Baek, K., Bourgeois, W., Sommerschield, A., Yue, H., Metivier, R. J., Karagiannis, P., Levitz, T. S., Xiong, Y., et al. (2026) · Science · doi:10.1126/science.aef5391 · Cited by 5
Metadata
- Authors
- Vincent, B. M., Marcoux, D., Caligioni, C., Bart, A. G., Harlow, M. L., Hsu, R. Y., Singh, P., Badger, R., Ingersoll, A. J., Jordan, T. B., Kamadurai, H. B., Zarate, C., Cantone, N. R., Medikonda, A. P., Alekseyenko, A. A., Nunes, D. E., Dauzhenka, T., Bhagwat, A., Rhee, D. Y., Arsenault, P. R., Conery, A. R., Constan, A., Plamondon, L., Wigle, T. J., La, D. S., Seyb, K. I., Trojer, P., & Palombella, V. J.
- Affiliations
- Triana Biomedicines, Lexington, MA.
- ORCID
- Venue
- Cancer Research
- Published
- 2026-04-03
- Volume
- 86
- Issue
- 7_Supplement
- Pages
- 5789-5789
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W7148692785
- Cited by
- 1
- References
- 0
- Citations by year
- 2026: 1
- Type
- conference abstract
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- cyclin E1, molecular glues, cereblon, CDK4/6 inhibitor resistance, hormone receptor-positive HER2-negative breast cancer, CDK2 inhibitors, CCNE1 amplification, solid tumors, targeted protein degradation, fulvestrant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Abstract 5789: Discovery of a selective molecular glue degrader of CCNE1 for the treatment of CCNE1-amplified solid tumors and CDK4/6i-resistant HR+/HER2- breast cancers. https://app.cochat.ai/papers/10.1158/1538-7445.am2026-5789
- The paper
- Vincent, B. M., Marcoux, D., Caligioni, C., Bart, A. G., Harlow, M. L., Hsu, R. Y., Singh, P., Badger, R., Ingersoll, A. J., Jordan, T. B., Kamadurai, H. B., Zarate, C., Cantone, N. R., Medikonda, A. P., Alekseyenko, A. A., Nunes, D. E., Dauzhenka, T., Bhagwat, A., Rhee, D. Y., . . . Palombella, V. J. (2026). Abstract 5789: Discovery of a selective molecular glue degrader of CCNE1 for the treatment of CCNE1-amplified solid tumors and CDK4/6i-resistant HR+/HER2- breast cancers. Cancer Research. https://doi.org/10.1158/1538-7445.am2026-5789
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.